Recent News

• 09.02.2025 - Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
• 09.02.2025 - Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
• 08.14.2025 - Q2 2025 Omeros Corporation Earnings Conference Call
• 08.14.2025 - Q2 2025 Omeros Corporation Earnings Conference Call
• 08.14.2025 - Omeros Corporation Reports Second Quarter 2025 Financial Results
• 08.14.2025 - Omeros Corporation Reports Second Quarter 2025 Financial Results
• 08.11.2025 - Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
• 08.11.2025 - Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
• 07.25.2025 - Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
• 07.25.2025 - Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Recent Filings

• 08.14.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - EX-99.1 EX-99.1
• 07.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.25.2025 - EX-99.1 EX-99.1
• 07.25.2025 - 8-K Current report
• 07.02.2025 - 8-K Current report
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities